Improving the development of generic skin medications.
Official title: Optimized clinical dermal Open Flow Microperfusion study design to demonstrate bioequivalence based on cutaneous pharmacokinetics
Funded at Joanneum Research Forschungsgesellschaft Mbh · NIH-10897842 · Data updated 2026-11-12
This study is testing a new way to show that generic skin medications work just as well as the brand-name ones, which could help make these more affordable options available for patients who need them.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Joanneum Research Forschungsgesellschaft Mbh NIH-funded |
| Lab location | 1 site (Graz, Austria) |
| Project start | September 15, 2022 |
| Project end | August 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $328,500 |
| NIH project number | 5U01FD007669-03 |
| Project ID | NIH-10897842 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients who use topical medications and may benefit from lower-cost generic alternatives.
✕Less likely to help
Patients who do not use topical medications or who require specialized formulations that cannot be matched may not benefit from this research.
What this research studies
This research focuses on developing a new method to demonstrate that generic topical medications are equivalent to their brand-name counterparts. It utilizes a technique called dermal Open Flow Microperfusion to assess how drugs are absorbed through the skin. By comparing the pharmacokinetics of these medications, the study aims to provide a more cost-effective way to bring generic options to market, ultimately benefiting patients who rely on these treatments.
Why it matters
Potential benefit: If successful, this research could lead to more affordable generic topical medications for patients.
How similar studies have gone: Previous projects funded by the US-FDA have shown promise in using similar approaches to assess drug equivalence, indicating a potential for success in this area.
Where this research is happening
-
Joanneum Research Forschungsgesellschaft Mbh
Graz, Austria Active
Researchers
- Principal investigator: Sinner, Frank — Joanneum Research Forschungsgesellschaft Mbh
- Study coordinator: Sinner, Frank
Related research
Other NIH-funded projects on the same topics.
-
Sub-second acetylcholine release in the brain for Alzheimer’s dementia
A small, quick stimulations-based study aims to boost a brain chemical called acetylcholine to help people with Alzheimer’s disease by using a targeted brain stimulation approach.
-
Understanding how broadly neutralizing antibodies may help HIV cure trials
A study at UC San Francisco looks at how antibody medicines behave in people on and off HIV therapy to help design better cure strategies.
-
Improving HIV-related brain infections by studying how drugs reach the brain
This grant looks at how well drugs reach the brain and spine to treat HIV-related infections like cryptococcal meningitis and TB meningitis in people with AIDS.
-
Transdermal delivery patch for zanamivir to treat influenza in patients
A new skin patch delivers zanamivir to people with flu or at risk of flu, aiming for easier, safer treatment than pills.
-
Chesapeake-Ohio Pharmacokinetics Core supports cancer drug testing
A collaborative core lab helps researchers study how cancer drugs behave in the body to improve clinical trials and patient care.
-
Urine color test to check tuberculosis drug levels in children and adults
This project uses a simple urine color test to see whether children and adults with TB are getting enough of key TB medicines like rifampin.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.